Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Over the last 12 months, insiders at Arcus Biosciences, Inc. have bought $320M and sold $2.75M worth of Arcus Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Arcus Biosciences, Inc. have bought $140.4M and sold $2.99M worth of stock each year.
Highest buying activity among insiders over the last 12 months: GILEAD SCIENCES, INC. (10 percent owner) — $1.6B.
The last purchase of 15,238,095 shares for transaction amount of $320M was made by GILEAD SCIENCES, INC. (10 percent owner) on 2024‑01‑29.
2024-08-13 | Sale | Chief Accounting Officer | 1,357 0.0015% | $14.97 | $20,314 | 0.00% | ||
2024-03-27 | Sale | Chief Operating Officer | 11,551 0.0123% | $17.55 | $202,720 | -11.31% | ||
2024-03-18 | Sale | Chief Operating Officer | 13,449 0.0154% | $17.92 | $240,941 | -5.57% | ||
2024-02-27 | Sale | President | 23,132 0.0255% | $20.10 | $464,953 | -18.68% | ||
2024-02-27 | Sale | Chief Operating Officer | 34,070 0.0376% | $20.11 | $685,148 | -18.68% | ||
2024-02-26 | Sale | President | 3,900 0.0044% | $20.06 | $78,234 | -16.48% | ||
2024-02-26 | Sale | Chief Operating Officer | 24,555 0.0276% | $20.07 | $492,819 | -16.48% | ||
2024-01-29 | 10 percent owner | 15.24M 28.0689% | $21.00 | $320M | +7.64% | |||
2024-01-02 | Sale | President | 6,975 0.0096% | $20.09 | $140,128 | -16.06% | ||
2024-01-02 | Sale | Chief Financial Officer | 2,004 0.0027% | $20.00 | $40,080 | -16.06% | ||
2023-12-22 | Sale | Chief Operating Officer | 21,521 0.028% | $17.76 | $382,213 | -9.97% | ||
2023-12-01 | Sale | Chief Accounting Officer | 282 0.0004% | $14.95 | $4,216 | +2.69% | ||
2023-09-22 | Sale | Chief Operating Officer | 21,369 0.0291% | $19.99 | $427,166 | -17.33% | ||
2023-07-28 | Sale | Chief Operating Officer | 45,000 0.0639% | $20.25 | $911,250 | -16.91% | ||
2023-07-03 | Sale | Chief Accounting Officer | 1,018 0.0014% | $20.41 | $20,777 | -17.18% | ||
2023-06-28 | 10 percent owner | 1.01M 1.3257% | $19.26 | $19.45M | -15.57% | |||
2023-06-22 | Sale | Chief Operating Officer | 12,437 0.0169% | $19.12 | $237,795 | -11.36% | ||
2023-06-16 | Sale | Chief Operating Officer | 12,563 0.017% | $19.35 | $243,094 | -11.87% | ||
2023-06-07 | Sale | Chief Financial Officer | 4,049 0.0054% | $20.04 | $81,142 | -15.94% | ||
2023-03-16 | Sale | Chief Operating Officer | 8,729 0.0119% | $16.81 | $146,734 | +7.46% |
GILEAD SCIENCES, INC. | 10 percent owner | 30061124 32.8495% | $15.44 | 3 | 0 | <0.0001% |
Jaen Juan C. | President | 1188233 1.2985% | $15.44 | 8 | 9 | <0.0001% |
Jarrett Jennifer | Chief Operating Officer | 215253 0.2352% | $15.44 | 0 | 24 | |
Goeltz II Robert C. | Chief Financial Officer | 51831 0.0566% | $15.44 | 1 | 5 | +33.11% |
Azoy Alexander | Chief Accounting Officer | 19070 0.0208% | $15.44 | 0 | 3 | |
ROSEN TERRY J | Chief Executive Officer | 242173 0.2646% | $15.44 | 21 | 6 | <0.0001% |
FALBERG KATHRYN E | director | 102106 0.1116% | $15.44 | 7 | 0 | +8.71% |
Tang Carolyn C. | General Counsel | 28584 0.0312% | $15.44 | 0 | 6 | |
Grossman William | Chief Medical Officer | 20723 0.0226% | $15.44 | 3 | 5 | +93.38% |
KANEKO YASUNORI | director | 7133 0.0078% | $15.44 | 1 | 0 | <0.0001% |
BlackRock | $186.92M | 10.89 | 9.9M | -1.34% | -$2.55M | <0.01 | |
State Street | $92.6M | 5.39 | 4.9M | +15.68% | +$12.55M | <0.01 | |
The Vanguard Group | $90.46M | 5.27 | 4.79M | +2.36% | +$2.09M | <0.01 | |
Fidelity Investments | $90.23M | 5.26 | 4.78M | +1.07% | +$953,194.56 | 0.01 | |
Woodline Partners LP | $54.44M | 3.17 | 2.88M | +178% | +$34.86M | 0.47 | |
Point72 Asset Management | $36.15M | 2.11 | 1.91M | +149.1% | +$21.64M | 0.05 | |
Dimensional Fund Advisors | $30.61M | 1.78 | 1.62M | +1.68% | +$505,984.00 | 0.01 | |
Invus Financial Advisors Llc | $30.44M | 1.77 | 1.61M | 0% | +$0 | 24.2 | |
Boxer Capital, LLC | $30.25M | 1.76 | 1.6M | 0% | +$0 | 0.62 | |
Ameriprise Financial | $22.68M | 1.32 | 1.2M | -26.53% | -$8.19M | 0.01 | |
Geode Capital Management | $22.13M | 1.29 | 1.17M | +2.61% | +$562,693.10 | <0.01 | |
AllianceBernstein | $21.73M | 1.27 | 1.15M | -2.94% | -$657,326.09 | 0.01 | |
Suvretta Capital Management, LLC | $18.07M | 1.05 | 957,304 | 0% | +$0 | 0.76 | |
Morgan Stanley | $16.52M | 0.96 | 874,882 | +24.73% | +$3.28M | <0.01 | |
Laurion Capital Management LP | $10.34M | 0.6 | 547,474 | New | +$10.34M | 0.07 | |
Northern Trust | $9.69M | 0.57 | 513,498 | -2.13% | -$211,286.10 | <0.01 | |
Charles Schwab | $9.31M | 0.54 | 493,276 | +4.47% | +$398,254.72 | <0.01 | |
BNY Mellon | $7.56M | 0.44 | 400,169 | -4.21% | -$332,004.81 | <0.01 | |
Panagora | $7.37M | 0.43 | 390,299 | +70.44% | +$3.05M | 0.04 | |
Macquarie Group | $7.16M | 0.42 | 379,100 | 0% | +$0 | 0.01 | |
Ubs Asset Management Americas Inc | $7.14M | 0.42 | 378,063 | -5.17% | -$388,984.62 | <0.01 | |
Citadel Advisors LLC | $6.7M | 0.39 | 354,921 | +28.63% | +$1.49M | <0.01 | |
Rafferty Asset Management Llc | $6.41M | 0.37 | 339,667 | +35.11% | +$1.67M | 0.02 | |
Citigroup | $5.97M | 0.35 | 316,127 | +148.47% | +$3.57M | <0.01 | |
Susquehanna International Group | $5.95M | 0.35 | 315,051 | +169.79% | +$3.74M | 0.01 | |
Granahan Investment Management | $5.6M | 0.33 | 296,570 | +28.51% | +$1.24M | 0.2 | |
Two Sigma | $4.97M | 0.29 | 263,277 | +132.84% | +$2.84M | 0.01 | |
Parkman Healthcare Partners Llc | $4.91M | 0.29 | 259,920 | +4.95% | +$231,393.30 | 0.61 | |
Nordea Investment Management Ab | $4.89M | 0.29 | 259,372 | +26.26% | +$1.02M | 0.01 | |
Goldman Sachs | $4.73M | 0.28 | 250,313 | -57.74% | -$6.46M | <0.01 | |
Eventide Asset Management | $4.53M | 0.26 | 240,000 | 0% | +$0 | 0.07 | |
Renaissance Technologies | $4.54M | 0.26 | 240,500 | +94.74% | +$2.21M | 0.01 | |
AXA | $4.38M | 0.26 | 232,072 | +0.03% | +$1,189.44 | 0.01 | |
DAFNA Capital Management, LLC | $4.37M | 0.26 | 231,717 | -0.43% | -$18,880.00 | 0.11 | |
UBS | $3.94M | 0.23 | 208,729 | +28.46% | +$873,105.71 | <0.01 | |
PLATINUM INVESTMENT MANAGEMENT LTD | $3.86M | 0.23 | 204,398 | 0% | +$0 | 0.05 | |
Invesco | $3.6M | 0.21 | 190,683 | -1.01% | -$36,759.36 | <0.01 | |
Barclays | $3.55M | 0.21 | 187,871 | -7.4% | -$283,694.96 | <0.01 | |
Gilder Gagnon Howe & Co. LLC | $3.3M | 0.19 | 174,655 | +25.5% | +$669,957.53 | 0.04 | |
RhumbLine Advisers | $3.26M | 0.19 | 172,673 | +0.78% | +$25,204.60 | <0.01 | |
Hudson Bay Capital Management LP | $3.12M | 0.18 | 165,000 | -2.94% | -$94,400.00 | 0.02 | |
Legal & General | $2.84M | 0.17 | 150,252 | +0.89% | +$24,959.37 | <0.01 | |
Bank of America | $2.82M | 0.16 | 149,552 | -9.3% | -$289,619.33 | <0.0001 | |
Nuveen | $2.4M | 0.14 | 127,219 | -4.67% | -$117,584.65 | <0.01 | |
Public Sector Pension Investment Board | $2.11M | 0.12 | 111,846 | 0% | +$0 | 0.02 | |
Schonfeld Group | $1.96M | 0.11 | 103,860 | -55% | -$2.4M | 0.01 | |
New York State Teachers Retirement System | $1.88M | 0.11 | 99,751 | 0% | +$0 | <0.01 | |
Allianz Asset Management Gmbh | $1.86M | 0.11 | 98,300 | +321.89% | +$1.42M | <0.01 | |
PDT Partners | $1.83M | 0.11 | 97,152 | +548.8% | +$1.55M | 0.14 | |
Swiss National Bank | $1.8M | 0.11 | 95,396 | 0% | +$0 | <0.01 |